IN THE CLAIMS

- 1. (canceled)
- (currently amended) A method of screening for therapeutic agents useful in the treatment of a cardiovascular disease in a mammal, comprising steps of:
 - determining the activity of a PDE10A polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
 - determining the activity of said polypeptide at a different concentration of said test compound; and
 - iii) identifying said test compound as a potential therapeutic agent useful in the treatment of the cardiovascular disease if it modulates the activity of the pDE10A polypeptide.
 - 3-26. (canceled)
- 27. (currently amended) A method of screening for therapeutic agents useful in the treatment of a disease selected from the group consisting of cancer, <u>liver gastroenterological</u> diseases; <u>diabetes endoerinological diseases</u>; and <u>kidney urological</u> diseases in a mammal, comprising steps of
 - determining the activity of a PDE10A polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
 - determining the activity of said polypeptide at a different concentration of said test compound; and
 - iii) identifying said test compound as a potential therapeutic agent useful in the treatment of the disease if it modulates the activity of the pDE10A polypeptide.

- 28. (currently amended) A method of screening for therapeutic agents useful in the treatment of Alzheimer's disease, comprising steps of
 - i) determining the activity of a PDE10A polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
 - ii) determining the activity of said polypeptide at a different concentration of said test compound; and
 - iii) identifying said test compound as a potential therapeutic agent useful in the treatment of the disease if it modulates the activity of the pDE10A polypeptide.